Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02167789 · ClinicalTrials.gov registry record · Phase 3
Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device
A Phase 3 study of Heart Failure, sponsored by LivaNova.
- Completed
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT02167789 is a Phase 3 study of Heart Failure that has completed, run by LivaNova. The registered enrollment target is 520 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT02167789, a Phase 3 study of Heart Failure, has completed, sponsored by LivaNova.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical investigation is a prospective, non-randomized, multi-center, pivotal trial.This trial is being performed in order to demonstrate the sensivity of the diagnostic feature "Physiological Diagnostic" (PhD).
Conditions Studied
Interventions
- DEVICE Paradym CRT 8770
Study Locations (20)
Arizona
- Dr. Haines - Kaplan, Phoenix,
- Drs. Lewis, Garg - Siegel, Phoenix,
Quebec
- Dr. Champagne, Dr. Philippon - Québec
- Drs. Thibualt, Guerra - Québec
Nantes
- Dr. Burban - Nantes
- Dr Abbey - Nantes
Massachusetts
- Drs. Jagmeet Singh, Kevin, Hiest - Boston
New York
- Drs. John Fisher, Jay Gross - Montefiore, Bronx NY
South Carolina
- Dr. Gold - Charleston
Angers
- Dr. Dupuis - Angers
Grenoble
- Dr. Defaye - Grenoble
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02167789
The ClinicalTrials.gov registry entry for NCT02167789 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (75% lower). The listed sponsor is LivaNova, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Paradym CRT 8770 is the first listed.
NCT02167789 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Arizona, Quebec, Nantes.
Frequently Asked Questions
What is clinical trial NCT02167789 about?
NCT02167789 is a clinical study titled "Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device". This clinical investigation is a prospective, non-randomized, multi-center, pivotal trial.This trial is being performed in order to demonstrate the sensivity of the diagnostic feature "Physiological Diagnostic" (PhD).
What is the current status of trial NCT02167789?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 520 participants. The study started on 2009-09. Estimated completion is 2013-06.
What conditions does trial NCT02167789 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT02167789?
The interventions under investigation include: Paradym CRT 8770 (DEVICE).
Who is sponsoring clinical trial NCT02167789?
This trial is sponsored by LivaNova, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02167789 being conducted?
This trial has 20 study locations across Arizona, Massachusetts, New York, South Carolina, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.